Background/Aims: To determine the effect of vitamin D3 supplementation on 25-hydroxyvitamin D [25(OH)D], lipid profile and markers of insulin resistance in obese adolescents. Methods: In this double-blind, randomized, placebo-controlled trial, 58 obese adolescents (n = 58; 12-18 years of age) received either vitamin D3 (2,000 IU/day) or placebo for 12 weeks. Total 25(OH)D, fasting plasma glucose, insulin and lipid profile were measured at baseline and following supplementation. Results: The trial was completed by 44/58 enrolled participants. At the end of the 12 weeks, total serum 25(OH)D concentrations increased to a modest degree (median 6 ng/ml) in the vitamin D-supplemented group (p < 0.001). Supplementation showed no detectable changes in fasting plasma glucose, insulin, homeostatic model of assessment index (HOMA-IR), lipids and highly sensitive C-reactive protein. Conclusions: 12 weeks of vitamin D3 supplementation in obese adolescents with 2,000 IU once daily resulted in a modest increase in 25(OH)D concentration in obese adolescents, but did not affect the lipid profile and markers of insulin resistance and inflammation. Further studies with higher doses of vitamin D3 and/or longer duration of supplementation are needed to understand if vitamin D3 supplementation can impact lipid profiles and markers of insulin resistance and inflammation in obese children.

Keywords:
Vitamin D3 supplementation, Serum 25(OH)D, Insulin resistance, Obese adolescents
1.
Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ: Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004;158:531-537.
2.
Rovner AJ, O'Brien KO: Hypovitaminosis D among healthy children in the United States: a review of the current evidence. Arch Pediatr Adolesc Med 2008;162:513-519.
3.
Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA: Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 2008;88:1519-1527.
4.
Harkness LS, Bonny AE: Calcium and vitamin D status in the adolescent: key roles for bone, body weight, glucose tolerance, and estrogen biosynthesis. J Pediatr Adolesc Gynecol 2005;18:305-311.
5.
Turer CB, Lin H, Flores G: Prevalence of vitamin D deficiency among overweight and obese US children. Pediatrics 2013;131:e152-e161.
6.
Kumar J, Muntner P, Kaskel FJ, Hailpern SM, Melamed ML: Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics 2009;124:e362-e370.
7.
Holick MF: Vitamin D deficiency. N Engl J Med 2007;357:266-281.
8.
Hill TR, Cotter AA, Mitchell S, Boreham CA, Dubitzky W, Murray L, Strain JJ, Flynn A, Robson PJ, Wallace JM, Kiely M, Cashman KD: Vitamin D status and its determinants in adolescents from the Northern Ireland Young Hearts 2000 cohort. Br J Nutr 2008;99:1061-1067.
9.
Houghton LA, Szymlek-Gay EA, Gray AR, Ferguson EL, Deng X, Heath AL: Predictors of vitamin D status and its association with parathyroid hormone in young New Zealand children. Am J Clin Nutr 2010;92:69-76.
10.
Smotkin-Tangorra M, Purushothaman R, Gupta A, Nejati G, Anhalt H, Ten S: Prevalence of vitamin D insufficiency in obese children and adolescents. J Pediatr Endocrinol Metab 2007;20:817-823.
11.
Dietz WH: Health consequences of obesity in youth: childhood predictors of adult disease. Pediatrics 1998;101:518-525.
12.
Reilly JJ, Methven E, McDowell ZC, Hacking B, Alexander D, Stewart L, Kelnar CJ: Health consequences of obesity. Arch Dis Child 2003;88:748-752.
13.
Pittas AG, Lau J, Hu FB, Dawson-Hughes B: The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007;92:2017-2029.
14.
Ashraf A, Alvarez JA: Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol 2010;2010:351385.
15.
Reis JP, Von Mühlen D, Miller ER III, Michos ED, Appel LJ: Vitamin D status and cardiometabolic risk factors in the United States adolescent population. Pediatrics 2009;124:e371-e379.
16.
Johnson MD, Nader NS, Weaver AL, Singh R, Kumar S: Relationships between 25-hydroxyvitamin D levels and plasma glucose and lipid levels in pediatric outpatients. J Pediatr 2010;156:444-449.
17.
Olson ML, Maalouf NM, Oden JD, White PC, Hutchison MR: Vitamin D deficiency in obese children and its relationship to glucose homeostasis. J Clin Endocrinol Metab 2012;97:279-285.
18.
Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL: 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 2002;11:1-190.
19.
Lensmeyer GL, Wiebe DA, Binkley N, Drezner MK: HPLC method for 25-hydroxyvitamin D measurement: comparison with contemporary assays. Clin Chem 2006;52:1120-1126.
20.
Belenchia AM, Tosh AK, Hillman LS, Peterson CA: Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: a randomized controlled trial. Am J Clin Nutr 2013;97:774-781.
21.
Pittas AG, Harris SS, Stark PC, Dawson-Hughes B: The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 2007;30:980-986.
22.
Jorde R, Sneve M, Torjesen P, Figenschau Y: No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med 2010;267:462-472.
23.
Von Hurst PR, Stonehouse W, Coad J: Vitamin D supplementation reduces insulin resistance in South-Asian women living in New Zealand who are insulin-resistant and vitamin D-deficient - a randomised, placebo-controlled trial. Br J Nutr 2010;103:549-555.
24.
Rajakumar K, de las Heras J, Lee S, Holick MF, Arslanian SA: 25-Hydroxyvitamin D concentrations and in vivo insulin sensitivity and β-cell function relative to insulin sensitivity in black and white youth. Diabetes Care 2012;35:627-633.
25.
Ashraf A, Alvarez J, Saenz K, Gower B, McCormick K, Franklin F: Threshold for effects of vitamin D deficiency on glucose metabolism in obese female African-American adolescents. J Clin Endocrinol Metab 2009;94:3200-3206.
26.
Andersen R, Brot C, Mejborn H, MØlgaard C, Skovgaard LT, Trolle E, Ovesen L: Vitamin D supplementation does not affect serum lipids and lipoproteins in Pakistani immigrants. Eur J Clin Nutr 2009;63:1150-1153.
27.
Scragg R, Sowers M, Bell C: Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004;27:2813-2818.
28.
Alemzadeh R, Kichler J, Babar G, Calhoun M: Hypovitaminosis D in obese children and adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season. Metabolism 2008;57:183-191.
29.
Aguirre Castaneda R, Nader N, Weaver A, Singh R, Kumar S: Response to vitamin D3 supplementation in obese and non-obese Caucasian adolescents. Horm Res Paediatr 2012;78:226-231.
30.
Harel Z, Flanagan P, Forcier M, Harel D: Low vitamin D status among obese adolescents: prevalence and response to treatment. J Adolesc Health 2011;48:448-452.
31.
Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF: Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690-693.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.